GCA
NBIX icon

Greenwood Capital Associates’s Neurocrine Biosciences NBIX Stock Holding History

Greenwood Capital Associates’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-37,703
Closed -$3.67M – 223
2021
Q1 		$3.67M Sell
37,703
-14,173
-27% -$1.49M 0.58% 60
2020
Q4 		$4.97M Sell
51,876
-6,198
-11% -$599K 0.84% 42
2020
Q3 		$5.58M Buy
58,074
+55,641
+2,287% +$6.44M 1.08% 35
2020
Q2 		$297K Sell
2,433
-37
-1% -$4.09K 0.07% 139
2020
Q1 		$214K Buy
2,470
+410
+20% +$40.1K 0.06% 139
2019
Q4 		$221K Buy
+2,060
New +$216K 0.05% 179

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
DCP
DSM Capital Partners Palm Beach Gardens, Florida $5.84B AUM 22.63% 1-Year Est. Return

Greenwood Capital Associates's NBIX Position: Q2 2021 in Review

Greenwood Capital Associates sold out of Neurocrine Biosciences (NBIX) in Q2 2021, closing a stake of 37,703 shares — an estimated $3.67M sold.

Greenwood Capital Associates first reported a position in NBIX in Q4 2019 and held it in 6 quarters. The position peaked at $5.58M in Q3 2020. 409 funds tracked by Wall St. Rank hold NBIX as of Q2 2021.

  • Greenwood Capital Associates reported no remaining Neurocrine Biosciences position as of Q2 2021 after selling out during the quarter.
  • Greenwood Capital Associates sold 37,703 Neurocrine Biosciences shares in Q2 2021, an estimated $3.67M.
  • Greenwood Capital Associates first reported a position in Neurocrine Biosciences in Q4 2019 and held it in 6 quarters.
  • Greenwood Capital Associates's Neurocrine Biosciences position peaked at $5.58M in Q3 2020.
  • 409 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2021.

Based on Greenwood Capital Associates's 13F filing for Q2 2021, filed 16 Aug 2021.